Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update
26 Marzo 2024 - 2:30PM
Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the
“Company”), a fully integrated contract development and
manufacturing organization (“CDMO”), announced today that Ernst
& Young LLP, the Company’s independent registered public
accounting firm for the fiscal year ended May 28, 2023, determined
that it declined to stand for reappointment as the Company’s
independent registered public accounting firm for the Company’s
fiscal year ending May 26, 2024 following the filing of the
Company’s Annual Report on Form 10-K. Lifecore’s board of directors
has initiated a search for a replacement.
In addition, the Company expects to provide a
business update on Monday, April 1, 2024, which is expected to
include certain select financial data for fiscal year 2024 and an
update on commercial business matters.
About Lifecore Biomedical
Lifecore Biomedical, Inc. is a fully integrated
contract development and manufacturing organization (CDMO) that
offers highly differentiated capabilities in the development, fill
and finish of complex sterile injectable pharmaceutical products in
syringes and vials. As a leading manufacturer of premium,
injectable grade Hyaluronic Acid, Lifecore brings more than 40
years of expertise as a partner for global and emerging
biopharmaceutical and biotechnology companies across multiple
therapeutic categories to bring their innovations to market. For
more information about the Company, visit Lifecore’s website at
www.lifecore.com.
Important Cautions Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements regarding future events and our future
results that are subject to the safe harbor created under the
Private Securities Litigation Reform Act of 1995 and other safe
harbors under the Securities Act of 1933 and the Securities
Exchange Act of 1934. Words such as “anticipate”, “estimate”,
“expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”,
“will”, “should”, “can have”, “likely” and similar expressions are
used to identify forward-looking statements. All forward-looking
statements involve certain risks and uncertainties that could cause
actual results to differ materially, including such factors among
others, as the outcome of any evaluation of the Company’s strategic
alternatives or any discussions with any potential bidders related
thereto, the Company’s ability to become current with its reports
with the Securities and Exchange Commission (the “SEC”), and the
timing thereof, the Company’s ability to regain compliance with
applicable listing standards under Nasdaq, and its ability expand
its relationship with its existing customers. For additional
information about factors that could cause actual results to differ
materially from those described in the forward-looking statements,
please refer to our filings with the SEC, including the risk
factors contained in our most recent Annual Report on Form 10-K.
Forward-looking statements represent management’s current
expectations and are inherently uncertain. Except as required by
law, we do not undertake any obligation to update forward-looking
statements made by us to reflect subsequent events or
circumstances.
Lifecore Biomedical, Inc. Contact
Information:Jeff Sonnek(646)
277-1263jeff.sonnek@icrinc.com
Lifecore Biomedical (NASDAQ:LFCR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lifecore Biomedical (NASDAQ:LFCR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024